| 查看: 629 | 回复: 5 | |||
[交流]
美国内布拉斯加大学医学中心招聘生物材料与组织再生方向博后
|
|||
|
A postdoctoral fellow position is available in the Xie laboratory within the Department of Surgery and Holland Regenerative Medicine Program at University of Nebraska Medical Center. Studies in our laboratory are focused on the design of nanofiber scaffolds for regenerative medicine. Both small (rodent) and large (swine) animal models of tissue repair in the skin, bone, nerve, muscle, and cartilage are employed. In addition, our laboratory explores the mechanisms of constructive remodeling of tissue-engineered constructs by delineating how host tissue microenvironments interact, populate, and integrate into scaffold environments in vivo. Our group synergizes the expertise of clinicians, bioengineers, and molecular biologists in a dynamic research environment to produce clinically viable biomaterials. Experience with stem cells for regenerative medicine is required. Strong history of publications in the areas of regenerative medicine, biomaterials, drug delivery, and tissue engineering are required. Pathology and/or immunological expertise is a plus. The candidate should be able to work independently as well as with a team of investigators. Excellent communication skills, both oral and written, are essential and an established publication record in biomaterials and tissue engineering is desired. This is an outstanding opportunity for persons interested in ultimately pursuing a medical and/or bioengineering career path. Applicants must have a PhD, and/or MD. The positions are available immediately. Please send your CV to jingwei.xie@unmc.edu |
» 猜你喜欢
越来越担心硕士毕业后没有竞争力了
已经有14人回复
论文的挂名怎么评判贡献?基金申请中,排名第一的挂名文章
已经有3人回复
申博自荐 2篇一区TOP+1篇EI+2公开发明专利 2027博士申请
已经有3人回复
闲聊
已经有6人回复
申博求助
已经有4人回复
» 本主题相关商家推荐: (我也要在这里推广)
简单回复
tzynew2楼
2023-08-14 23:17
回复
chenshixua(金币+1): 谢谢参与
k 发自小木虫Android客户端
2023-08-15 07:17
回复
chenshixua(金币+1): 谢谢参与
XG-WUST4楼
2023-08-15 07:22
回复
chenshixua(金币+1): 谢谢参与
up 发自小木虫IOS客户端
2023-08-15 08:32
回复
chenshixua(金币+1): 谢谢参与
k1146楼
2023-08-15 17:53
回复










回复此楼